Mouse Monoclonal CD73 antibody. Suitable for Flow Cyt, WB, IHC-P and reacts with Human samples. Cited in 17 publications. Immunogen corresponding to Recombinant Fragment Protein within Human NT5E aa 1-250.
View Alternative Names
CD73, NT5, NTE, NT5E, 5'-nucleotidase, 5'-NT, 5'-deoxynucleotidase, Ecto-5'-nucleotidase, IMP-specific 5'-nucleotidase, Thymidylate 5'-phosphatase
- Flow Cyt
Supplier Data
Flow Cytometry - Anti-CD73 antibody [4G6E3] (AB202122)
Flow cytometric analysis of A431 cells using ab202122 at 1/200 (green) and negative control (red).
- IHC-P
Supplier Data
Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-CD73 antibody [4G6E3] (AB202122)
Immunohistochemical analysis of paraffin-embedded Human endometrial cancer tissue labeling CD73 with ab202122 at 1/200 with DAB staining.
- IHC-P
Supplier Data
Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-CD73 antibody [4G6E3] (AB202122)
Immunohistochemical analysis of paraffin-embedded Human esophageal cancer tissue labeling CD73 with ab202122 at 1/200 with DAB staining.
- WB
Lab
Western blot - Anti-CD73 antibody [4G6E3] (AB202122)
False colour image of Western blot : Anti-CD73 antibody [4G6E3] staining at 1/500 dilution, shown in green; Rabbit Anti-GAPDH antibody [EPR16891] (ab181602) loading control staining at 1/20000 dilution, shown in red. In Western blot, ab202122 was shown to bind specifically to CD73. A band was observed at 65-70 kDa in wild-type A-375 cell lysates with no signal observed at this size in NT5E knockout cell line ab281591 (knockout cell lysate ab282943). A cross-reactive band is observed at 65 kDa in all samples. To generate this image, wild-type and NT5E knockout A-375 cell lysates were analysed. First, samples were run on an SDS-PAGE gel then transferred onto a nitrocellulose membrane. Membranes were blocked in 3 % milk in TBS-0.1 % Tween® 20 (TBS-T) before incubation with primary antibodies overnight at 4 °C. Blots were washed four times in TBS-T, incubated with secondary antibodies for 1 h at room temperature, washed again four times then imaged. Secondary antibodies used were Goat anti-Mouse IgG H&L (IRDye® 800CW) preabsorbed (ab216772) and Goat anti-Rabbit IgG H&L (IRDye® 680RD) preabsorbed (ab216777) at 1/20000 dilution.
All lanes:
Western blot - Anti-CD73 antibody [4G6E3] (ab202122) at 1/500 dilution
Lane 1:
Wild-type A-375 cell lysate at 20 µg
Lane 2:
NT5E knockout A-375 cell lysate at 20 µg
Lane 2:
Western blot - Human NT5E knockout A375 cell line (<a href='/en-us/products/cell-lines/human-nt5e-knockout-a375-cell-line-ab281591'>ab281591</a>)
Lane 3:
A431 cell lysate at 20 µg
Lane 4:
HepG2 cell lysate at 20 µg
Predicted band size: 63 kDa
Observed band size: 65 kDa,65-70 kDa
false
- WB
Supplier Data
Western blot - Anti-CD73 antibody [4G6E3] (AB202122)
All lanes:
Western blot - Anti-CD73 antibody [4G6E3] (ab202122) at 1/500 dilution
All lanes:
A431 cell lysate
Predicted band size: 63 kDa
false
- WB
Lab
Western blot - Anti-CD73 antibody [4G6E3] (AB202122)
Lanes 1 - 3 : Merged signal (red and green). Green - ab202122 observed at 63 kDa. Red - loading control, ab181602, observed at 37 kDa.
ab202122 was shown to recognize NT5E in wild-type A-431 cells as signal was lost at the expected MW in NT5E knockout cells. Additional cross-reactive bands were observed in the wild-type and knockout cells. Wild-type and NT5E knockout samples were subjected to SDS-PAGE. ab202122 and ab181602 (Rabbit anti-GAPDH loading control) were incubated overnight at 4°C at 1/1000 dilution and 1/20000 dilution respectively. Blots were developed with Goat anti-Mouse IgG H&L (IRDye® 800CW) preabsorbed ab216772 and Goat anti-Rabbit IgG H&L (IRDye® 680RD) preabsorbed ab216777 secondary antibodies at 1/20000 dilution for 1 hour at room temperature before imaging.
All lanes:
Western blot - Anti-CD73 antibody [4G6E3] (ab202122) at 1/1000 dilution
Lane 1:
Wild-type A-431 whole cell lysate at 20 µg
Lane 2:
NT5E knockout A-431 (Human epidermoid carcinoma cell line) whole cell lysate at 20 µg
Lane 2:
Western blot - Human NT5E knockout A-431 cell line (<a href='/en-us/products/cell-lines/human-nt5e-knockout-a-431-cell-line-ab261895'>ab261895</a>)
Lane 3:
A375 (Human malignant melanoma cell line) whole cell lysate at 20 µg
Predicted band size: 63 kDa
false
- WB
Supplier Data
Western blot - Anti-CD73 antibody [4G6E3] (AB202122)
Expected MW is 26.6 kDa
All lanes:
Western blot - Anti-CD73 antibody [4G6E3] (ab202122) at 1/500 dilution
All lanes:
Human CD73 (AA: 30-250) recombinant protein
Predicted band size: 63 kDa
false
Reactivity data
Product details
Properties and storage information
Form
Purification technique
Purification notes
Storage buffer
Shipped at conditions
Appropriate short-term storage duration
Appropriate short-term storage conditions
Appropriate long-term storage conditions
Aliquoting information
Storage information
Supplementary information
This supplementary information is collated from multiple sources and compiled automatically.
Biological function summary
CD73 participates in the regulation of purinergic signaling through adenosine production. It acts in cooperation with other cell surface enzymes such as CD39 forming a functional complex that handles ATP breakdown to adenosine. This enzymatic activity modulates immune responses tissue protection and inflammation control. In addition to immune-related functions CD73 supports the maintenance of vascular integrity and proper cellular adhesion which is important in different physiological and pathological contexts.
Pathways
CD73 plays an important part in the adenosinergic pathway governing the conversion of AMP into adenosine. This activity impacts the signaling and function of the adenosine receptors on immune and non-immune cells. Another important pathway is the angiogenesis process where CD73 contributes by affecting endothelial cell migration and blood vessel development. Relationships with key proteins such as adenosine A2 receptors help facilitate these critical pathway activities.
Product protocols
- Visit the General protocols
- Visit the Troubleshooting
Target data
Publications (17)
Recent publications for all applications. Explore the full list and refine your search
Biomolecules & biomedicine 25:869-882 PubMed39226107
2024
Applications
Unspecified application
Species
Unspecified reactive species
iScience 27:109738 PubMed38706844
2024
Applications
Unspecified application
Species
Unspecified reactive species
International journal of molecular sciences 24: PubMed36769123
2023
Applications
Unspecified application
Species
Unspecified reactive species
Stem cells international 2023:6510571 PubMed36762032
2023
Applications
Unspecified application
Species
Unspecified reactive species
Cellular & molecular biology letters 27:86 PubMed36209059
2022
Applications
Unspecified application
Species
Unspecified reactive species
Disease markers 2022:6943630 PubMed36072901
2022
Applications
Unspecified application
Species
Unspecified reactive species
Journal of translational medicine 20:258 PubMed35672774
2022
Applications
Unspecified application
Species
Unspecified reactive species
Analytical cellular pathology (Amsterdam) 2022:9302496 PubMed35127344
2022
Applications
Unspecified application
Species
Unspecified reactive species
Journal of tissue engineering and regenerative medicine 16:311-329 PubMed34962086
2022
Applications
Unspecified application
Species
Unspecified reactive species
Bioengineered 12:9739-9752 PubMed34637682
2021
Applications
Unspecified application
Species
Unspecified reactive species
Product promise
Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.
For licensing inquiries, please contact partnerships@abcam.com